** Shares of Hims & Hers Health Inc surged to a record high, last up 19% and extending recent gains after raising its annual rev forecast last week
** HIMS reached as high as $29.68 during session; last at $28.00
** The telehealth firm on Nov. 5 raised its full-yr rev forecast to $1.46-$1.47 bln from $1.37-$1.40 bln and said it would add a generic version of Novo Nordisk's diabetes and weight loss drug, liraglutide, to its platform in 2025
** Soaring demand for weight-loss drugs made by Novo and Eli Lilly has led to shortages that allow them to be produced under U.S. regulations
** HIMS now up 213% YTD vs S&P 500's 26% increase
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.